Business Wire

Xandr Furthers Integrations with Industry IDs and Advances Proprietary Modelled and Contextual Solutions

27.10.2021 15:00:00 EEST | Business Wire | Press release

Share

Xandr, AT&T’s advanced advertising company, today announced investments which expand its portfolio of identity offerings. Earlier this year, Xandr announced a multi-faceted approach to balance customers’ advertising needs and consumer privacy, and has now delivered several addressability solutions through integrations with LiveRamp (NYSE:Ramp), netID and Unified ID 2.0, as well as publisher first-party data activation solutions, contextual and modelled capabilities.

Facilitating addressability through consumer-consented data is a key component that Xandr has made strides on. Through Xandr’s collaboration with LiveRamp, Xandr this year launched end-to-end support for RampID on its platform. Publishers using Xandr’s Monetize SSP have started to use RampIDs in their monetization strategies and have seen positive indications. Agencies and marketers are also beginning alpha tests for RampID capabilities on Xandr’s Invest DSP, which include data onboarding, targeting and measurement. Xandr and LiveRamp are also expanding their relationship in other ways, including LiveRamp becoming a partner on Xandr Curate, the platform for monetizing data through curated deals. Travis Clinger, SVP, addressability and ecosystem at LiveRamp comments: “Our mission has always been to make it safe and easy for our partners and customers to connect data, wherever data lives. Our continued and evolving partnership with Xandr helps make that possible programmatically, bringing the demand- and sell-sides closer together to ensure critical advertising workflows are more sustainable, efficient, and performant on a global scale. Further, Xandr's support of RampID, a high-fidelity, person-level, omnichannel identifier, takes our existing integration with them to the next level.”

First-party data will be key in the new era of advertising. Xandr has laid the foundation to roll out a suite of powerful tools which empower publishers to leverage their data assets to power relevant advertising, while still protecting the privacy needs of their users. Xandr’s publisher first-party data capabilities provide the necessary targeting, frequency management and privacy controls to enable scaled monetization across environments. Today, Xandr supports netID across multiple use cases, and continues to build upon this investment, working with netID, publishers and marketers on its platform. In 2022, Xandr will launch an enhanced Publisher ID suite providing additional capabilities, which is built to address publishers’ forward-looking needs. Providing publishers with the right tools to successfully execute business models, while ensuring that data is properly protected and users are in full control, will be of the utmost importance in this transformational shift in advertising”, says Achim Schlosser, CTO of the European netID Foundation. “First-party data is a key building block in future of digital marketing, which needs to be both user-friendly and sustainable. For that we need strong co-operation among the industry to enable a fair and open web.”

Whilst LiveRamp and netID integrations are complete, Xandr is collaborating with the industry to ensure readiness for the broader launch of the Unified ID 2.0 integration.

Alongside these integrations Xandr has advanced its modelled and contextual solutions utilizing data science, machine learning, and contextual data to enable relevant advertising in the absence of identifiers.

Xandr has been productizing its Real Time Signals offering (RTS) which enables audience activation by using contextual signals such as hyperlocal geolocation and URL to reach audiences in identity-less environments. RTS is a differentiating, scalable way to reach our clients’ desired customers in a privacy compliant manner and Xandr recently showcased this through its work with Dentsu.

Frequency management to avoid over-exposure is a critical need for publishers and marketers. As such, Xandr has developed an inventory classification model which does not rely on cookies or device/user level identifiers. This enables Xandr to infer one brand’s ad exposure to a user based on averages in real-time and make decisions on whether or not to bid for an impression, thereby enabling platform customers to prevent consumer ad fatigue and wasted spend without reliance on user identifiers.

Xandr understands that collaboration in the industry is the best approach to solving identity. With this in mind Xandr participated in the Google FLoC trial in June and July to better understand the solution. Xandr is continuing to work across industry groups to refine and test other proposals within this, including PARAKEET.

“Xandr is focused on the development of alternative solutions for its clients. Whilst integrations are an important part of this, as is first-party data activation solutions, Xandr is also heavily focused on offering modelled and contextual solutions of its own. During this time Xandr has also been working with customers on different testing opportunities and on Xandr’s platform, buyers and sellers are now able to target, frequency cap and measure outcomes” adds Ewa Maciukiewicz, VP, Product Management, Xandr. “Whilst there is no simple solution to identity, looking ahead to 2022 Xandr is focused on scaling addressability, simplifying first-party data activation, accelerating the connection between marketers and publishers, and thinking beyond identity to drive relevant advertising in non-addressable environments.”

ABOUT XANDR

A business unit within AT&T, Xandr powers a global marketplace for premium advertising. Our data-enabled technology platform, encompassing Xandr Invest and Xandr Monetize, optimizes return on investment for both buyers and sellers. For more than 143 years, AT&T has used data and technology to inform and improve the consumer experience.

ABOUT LiveRamp

LiveRamp is the leading data connectivity platform for the safe and effective use of data. Powered by core identity resolution capabilities and an unparalleled network, LiveRamp enables companies and their partners to better connect, control, and activate data to transform customer experiences and generate more valuable business outcomes. LiveRamp’s fully interoperable and neutral infrastructure delivers end-to-end addressability for the world’s top brands, agencies, and publishers. For more information, visit www.LiveRamp.com

ABOUT EUROPEAN NETID FOUNDATION

The European netID Foundation was founded in March 2018 by Mediengruppe RTL Deutschland, ProSiebenSat.1 and United Internet with the brands WEB.DE and GMX. With an independent market solution, the foundation supports Internet offerings of all industries in implementing the new European data protection law and has created the open login standard netID for this purpose. The initiators of the foundation together reach around 50 million unique users every month and together have more than 38 million active accounts. The foundation is explicitly open for further partners and other initiatives. Further information is available at www.enid.eu.

“We are proud that our netID identifier is supported by Xandr’s end-to-end platform. This gives content providers in Europe the possibility to easily deliver personalized advertising in compliance with data protection regulations and across devices,” says Sven Bornemann, CEO of the European netID Foundation. “As well, we are very much looking forward to our partnership and warmly welcome Xandr’s Thomas Mendrina to the Publishing/Ad Sales advisory board of the European netID Foundation.”

ABOUT UNIFIED ID 2.0

Unified ID 2.0 is a next-generation identity solution that is an open-source digital framework. With initial development led by The Trade Desk, Unified ID 2.0 is the result of broad collaboration among publishers, buyers and technology providers across the industry. It serves as an alternative to third-party cookies that aims to improve consumer transparency, privacy and control, while preserving the value exchange of relevant advertising across channels and devices.

Prebid.org, the independent organization designed to ensure and promote fair and transparent marketplaces across the industry, has agreed to serve as operator of Unified ID 2.0. Prebid.org will begin this role in the second half of this year.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Xandr
Kathryn Foster
kathryn.foster@xandr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye